Amarillo Biosciences (AMARD) 0.4000 $AMARD Amarillo

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Amarillo Biosciences (AMARD) 0.4000 $AMARD

Amarillo Biosciences, Inc. Summarizes New Plan of Operation
Marketwired - Mon May 18, 8:30AM CDT
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) (OTCQB: AMAR) today summarized its new operating plan following the Company's emergence from Chapter 11 Bankruptcy. ABI disclosed that it had arisen from bankruptcy January 23, 2015, when the Final Decree closing the case had been signed by Judge Robert L. Jones of the United States Bankruptcy Court for the Northern District of Texas in Case No. 13-20393-RJL-11.

Oral Proteins and Peptides Market, 2015 - 2025
M2 - Wed Feb 18, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/g33dxb/oral_proteins_and) has announced the addition of the "Oral Proteins and Peptides Market, 2015 - 2025" report to their offering. The Oral Proteins and Peptides Market (2nd edition), 2015-2025 report provides a comprehensive analysis of the current state of the market and the likely future evolution over the next ten years. Endogenous peptides are a smart way to utilise body's own resources to design drugs that are more specific and carry great potential to cure hard-to-treat diseases. The protein and peptide therapeutics market is a multi-billion dollar market and researchers are trying their best to improve the therapy by devising strategies for their oral delivery. The report portrays efforts of various pharmaceutical companies in making the transition towards oral delivery by developing innovative technologies and testing multiple drug candidates based on these technologies. A vast amount of activity is happening in this area as seen by the myriad of discoveries, patents, collaborations and grants. Highlights: - The market is characterized by the presence of 76 molecules in different phases of development.Four molecules are in the late stage clinical trials (phase III); of these, Oral Octreolin, Ostora and Plecanatide are likely to be made commercially available in 2016. - Diabetes stands out among the indication groups for which various molecules are in investigational studies. Nearly 37% of the total molecules under research are being developed for diabetic disorders. Other prominent areas include gastric disorders andbone diseases. - The market is not dominated by the presence of a big company or a group of companies. Several start-ups have led research efforts by developing the technologies that facilitate oral formulation of proteins and peptides. - Prominent technologies include Axcess, GIPET, Peptelligence and Disulfide Rich Peptides; a number of oral proteins and peptides are based on one of these technologies. - One of the primary drivers for growth in the industry is the rising venture capital interest and available funding from other avenues. In total, over the last 10 years, we identified total investment of close to USD 0.9 billion. - The current crop of oral proteins and peptides is likely to benefit from early success of Linzess; combined, we expect it to be a multi-billion dollar market growing at an annualised rate of 30% over the coming decade. Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. OVERVIEW AND MARKET BACKGROUND 5. DRUG PROFILES AND MARKET FORECAST 6. CASE STUDIES: LIPROTAMASE, SANDIMMUNE, DDAVP 7. TECHNOLOGY PLATFORMS 8. RECENT PARTNERSHIPS 9. VENTURE CAPITAL SUPPORT 10. SWOT ANALYSIS 11. CONCLUSION 12. APPENDIX 1: Tabulated Data 13. APPENDIX 2: List of Companies Companies Mentioned Following companies have been mentioned in the report: 30 of the 100 Companies Featured - Abbott Laboratories - AbbVie - Affilogic - AIMM Therapeutics - Alchemia - Almirall S.A. - Alnara Pharmaceuticals - Amarillo Biosciences - Anthera Pharmaceuticals - Apollo Life Sciences - Apotex - Aptalis Pharma - Arisgen - Armour - Astellas - AstraZeneca - Avaxia Biologics - Barr Pharmaceuticals - Biocon - Biodel Inc. - Bone Medical - Bristol-Myers Squibb - Cara Therapeutics - Centocor Ortho - Chiasma Pharmaceuticals - Clinigene - Cosmo Pharmaceuticals - Diabetology Ltd. - Diasome Pharma - Digestive Care Inc. Following Universities / Research Centres have been mentioned in this report: - Elan Biotechnology Research Centre, Trinity College, - Biomedical Advanced Research and Development Agency - BioScience Innovation Centre - Hadassit Medical Research - Tianjin International Joint Academy of Biomedicine - University of Southern California - National Institute of Health Following Venture Capital firms have been mentioned in this report: 30 of the 50 Plus Firms - 7 Med Health Ventures - Abingworth - Aegis Capital Corporation - Alta Biopharma Partners - ARCH Venture Partners - Ariel Southeast Angel Partners - Ascent Biomedical Ventures - Beacon Angels - Boston Harbor Angels - Cherrystone Angels - Connecticut Innovations - CT Innovations - Devon Park BioVentures - DNA Biomedical Solutions Ltd. - F2 Ventures - F3 Ventures - Foresite Capital - Fredric Price - GGV Capital - Golden Seeds - Google Ventures - Granite State Angels - Great Point Partners - Healthcare Private Equity - InCubeBioVentures - Jerusalem Global Ventures - Johnson and Johnson Development Corporation - LaunchPad Venture Group - Life Sciences Fund Amsterdam - Lilly Ventures For more information visit http://www.researchandmarkets.com/research/g3...oteins_and
JNJ: 123.86 (-0.04), ABT: 44.81 (-0.14), ANTH: 3.25 (+0.11), BMY: 75.32 (+0.52), BIOD: 0.40 (unch)

Drug Delivery Partnering Terms and Agreements 2015
M2 - Mon Feb 16, 10:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/rpgmrs/drug_delivery) has announced the addition of the "Drug Delivery Partnering Terms and Agreements" report to their offering. The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not. This report contains over 2,000 links to online copies of actual drug delivery deals and contract documents where available as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The drug delivery technology includes the following sub-technology areas: - Bioavailability - Implanatable - Oral delivery - Rapid release - Delayed release - Parenteral - Infusion - Injectable - Pro-drug - Targeted - Tropical - Transdermal - Buccal - Inhaled - Nasal - Ocular - Rectal - Sublingual - Urogenital Companies Mentioned: 30 of the 350 Companies that Feature in this Extensive Report - 3M - 3M Drug Delivery Systems - AAIPharma Services - Abbott - Accredo Health Group - Acelrx Pharmaceuticals - Acorda Therapeutics - Actavis - Actelion - Actient Pharmaceuticals - Adeona Pharmaceuticals - Adolor - Alchemia - Aldexa Therapeutics - Alexza Pharmaceuticals - Alfacell - Alimera Sciences - Alkermes - Allergan - Allos Therapeutics - Amag Pharmaceuticals - AMAG Pharmaceuticals - Amarillo Biosciences - Amarin - Amicus Therapeutics - Ampio Pharmaceuticals - Amylin Pharmaceuticals - Anesiva - Angiotech Pharmaceuticals - AP Pharma For more information visit http://www.researchandmarkets.com/research/rp...g_delivery About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
AMPE: 0.95 (-0.01), ACOR: 24.99 (+0.09), ALKS: 48.91 (-0.64), AGN: 253.45 (+0.92), ALDX: 5.73 (-0.27), ALIM: 1.76 (-0.24), AMAG: 27.24 (+0.23), FOLD: 6.82 (+0.03)

Amarillo Biosciences, Inc. Reorganizes, Exits Bankruptcy, and Opens a New Chapter in the Healthcare Industry
ACCESSWIRE - Mon Feb 02, 8:16AM CST
AMARILLO, TX / ACCESWIRE / February 2, 2015 / Amarillo Biosciences, Inc. (ABI) (OTC Pink: AMAR) (PINKSHEETS: AMAR), today announced that the Company has completely reorganized and emerged from the voluntary Chapter 11 Bankruptcy declared fifteen months ago. The Order and Final Decree closing the case was signed by Judge Robert L. Jones of the Northern District of Texas, on January 23, 2015.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

XPLR Infrastructure Faces Class Action Lawsuit Outcry

Updated Category News Views 170

Class Action Lawsuit Filed Against XPLR Infrastructure Levi & Korsinsky, LLP has announced a class action lawsuit concerning XPLR Infrastructure, LP, previously known as Nextera Energy Partners, LP. This lawsuit addresses significant concerns regarding securities fraud that impacted numerous investors, particularly those who held shares during the specified time frame....

Continue Reading
PharmAla Reports Impressive Growth and Key Milestones Achieved

Updated Category News Views 291

PharmAla Biotech Holdings Shareholder Update PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) has recently shared their financial and operational performance metrics providing insight into their notable achievements up to the end of May 2025. Focusing on the development and distribution of LaNeo™ MDMA, along with other novel...

Continue Reading
Discover the Bold New Batch of Sagamore Spirit Rye Whiskey

Updated Category News Views 387

Discover the Bold New Batch of Sagamore Spirit Rye Whiskey The 100% Maryland-made whiskey is 7-Years-Old and 123 Proof Sagamore Spirit, the celebrated Maryland rye distillery, is introducing a new batch of their award-winning Cask Strength Rye Whiskey. This exceptional spirit boasts a seven-year age profile and carries a robust ABV of 61.5%. The whiskey delights the...

Continue Reading
Stocks to Eye: Ciena, Oracle, and Other Market Movers Ahead

Updated Category News Views 166

Market Trends to Watch This Thursday As U.S. stock futures experience a downward shift, investors are keenly eyeing some significant stocks that could impact market movements today. Among them, several prominent companies are set to announce their earnings, potentially affecting their stock performance and overall market sentiment. Ciena Corp. on Investor's Radar Wall...

Continue Reading
The Perfect Franchise Conference Boosts Industry Engagement

Updated Category News Views 144

The Perfect Franchise Annual Conference: A Catalyst for Growth The Perfect Franchise (TPF), a leader in the realm of franchise consulting and coaching, has seen notable advancements, particularly in the wake of their annual conference. As the franchise industry blooms, this gathering serves not just as an event but as a beacon of growth for both franchise brands and...

Continue Reading